Wegovy and Zepbound are two FDA-approved weight loss drugs. Learn how they compare in benefits, side effects, and more to ...

Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

The FDA said it wants suicide warnings to be taken off some popular weight-loss medications following a comprehensive safety ...

By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U.S. in the first ...

President Donald Trump announced a new agreement with Eli Lilly and Novo Nordisk to expand coverage and lower prices for popular obesity drugs Zepbound and Wegovy, part of the GLP-1 class of ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.

However, not everyone is willing—or able—to indefinitely commit to GLP-1s.